$42.62
-3.13-6.84%
Last update: Nov 12, 7:35 PM
CRISPR Therapeutics AG
CRSPNASDAQ
CRISPR Therapeutics fell 10.5% from $51.11 to $45.75, behind the S&P 500's +12.7%. Its worst day was Apr 24 (−11.6%), and its low came Mar 30 at $44.34.
Nov 13, 2025 – Nov 11, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
CRISPR Therapeutics shares rose 11.1%, while the S&P 500 rose 0.5%.
+11.1% · S&P 500 +0.5%
EPS of $-1.37 missed the $-1.20 estimate on $864,000.00 revenue (est. $3.9M).
+8.5% · S&P 500 +0.1%
Story events cover the past 12 months · Times ET
CRISPR Therapeutics shares rose 11.8%, while the S&P 500 fell 0.6%.
+11.8% · S&P 500 −0.6%
CRISPR Therapeutics closed at its lowest level of the year, 13.2% below where the year started.
−3.1% · S&P 500 −0.3%
CRISPR Therapeutics shares fell 11.6%, while the S&P 500 rose 0.8%.
−11.6%, the year's worst day · S&P 500 +0.8%
EPS of $-1.28 missed the $-1.22 estimate on $1.5M revenue (est. $5.1M).
−2.2% · S&P 500 +0.8%
CRISPR Therapeutics closed at its highest level of the year, 21.1% above where the year started.
+3.0% · S&P 500 +0.9%
EPS of $-0.94 beat the $-1.18 estimate on $10.2M revenue (est. $7.1M).
+7.1% · S&P 500 +1.8%
CRISPR Therapeutics shares rose 12.9%, while the S&P 500 rose 0.2%.
+12.9%, the year's best day · S&P 500 +0.2%
EPS of $-1.15 missed the $-1.06 estimate on $12.7M revenue (est. $15.2M).
−2.8% · S&P 500 −0.5%
Where it ended: a close of $45.75 on Nov 11, 2026. Up next: Q4 2026 earnings on Feb 11, 2027 (EPS est. $-1.13, revenue est. $10.7M).
Nothing in the past 12 months.
All CRSP dividend historyReplay the year: the line draws itself and stops at each of the 10 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for CRSP and SPY from Benzinga historical bars. Not investment advice.
